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Improved Survival With Cytomegalovirus Infection After Intestinal 
Transplantation in Children 
J. Bueno, M. Green, J. Reyes, N. Jabbour, S. Kocoshis, E. Yunis, S. Todo, and T.E. Starzl 
I NTESTINAL transplantation (ITx) is now feasible with 
actuarial patient and graft survivals at 24 months ex-
ceeding 74% and 59%, respectively.l The occurrence of 
opportunistic infections such as cytomegalovirus (CMV), 
however, has significantly hindered further improvement in 
long term outcome. In this study, we focus upon our 
experience with CMV after ITx in children and analyze the 
influence of CMV infections upon postoperative outcome. 
MATERIALS AND METHODS 
Patient Population 
Between 1990 to 1995, 41 children received 44 ITx under tacroli-
mus and steroid immunosuppression. Transplants included: iso-
lated small bowel (S8) (n = 10), liver-S8 (L-S8) (n = 27), and 
multivisceral (MV) (n = 7) allografts. There were 19 males and 22 
females with ages ranging between 0.5 to 18 years (mean of 4.2 
years). The donor and recipient surgical procedures were as 
previously described.2 Indications as well as graft surveillance. 
immunosuppression, and nutritional management have been re-
ported elsewhere. 1•3 All but the last seven recipients have been 
followed for 1 to 5 years. 
Incidence and outcome of CMV disease (CMVD) were analyzed 
for all recipients by donor (D)-recipient (R) serologic status (e.g. 
D-/R-, D+/R-, D-/R+, D+/R+) using previously established 
criteria.' 
Prophylaxis and Treatment 
Eight patients received prophylaxis with acyclovir (5 mg/kg) twice a 
day for 2 to 3 weeks, and 31 patients received intravenous 
ganciclovir (10 mglkg) in 2 daily doses for the lirst 2 weeks after 
transplantation. Three of these were given concommitant hyperim-
muneglobulin (100 mg/kg/d). Two patients did not receive prophy-
laxis. Episodes of CMV disease were treated with ganciclovir alone 
or in combination with CMV-specilic hyperimmuneglobulin. Im-
munosuppression was maintained at a therapeutic baseline and 
reduced only in the face of deteriorating clinical disease. 
RESULTS 
Fifteen patients were serologically negative pretransplant 
for CMV and received organs from CMV negative donors 
(D-/R-): none of these 15 patients developed CMVD. 
Twenty-six children were positive for donor or recipient or 
both CMV serologies and were distributed as follows: 
D+/R- (n = R). three patients (37.5%) dcveloped CMVD: 
D+/R+ (n := l). three patients developed CMVD (J.13':';): 
D-/R+ (n := l), four patients developed CMVD E~4 .. V'r). 
Fifteen episodes of CMVD were documented among these 
10 patients. Resolution of disease occurred in l)O"i of 
patients. The distribution of CMVD according to organ 
involved were: intestinal allograft enteritis (11 = 7), allograft 
gastritis (n = I). native gastroduodenitis (n = 2). native 
colitis (n := 2), pneumonitis (n = 3). The pneumonitis was 
not associated with major changes in the clinical status of 
the patients. Recurrent CMVD occurred in five patients 
(50%): two were D+/R- patients, two were D-/R+ and 
one was a D+/R+ patient. Of these recurrences, three 
occurred in the allograft intestine. Persistent CMVD oc-
curred in two patients (including one of the five patients 
with recurrent disease) who were from the D+/R- sub-
group; resolution of disease occurred in both patients after 
7 months of therapy. The incidence of CMVD in the at risk 
children (excluding D - /R - recipients) according to allo-
graft type was: SB 3/4, L-SB 5/19, MV 2/3. 
Three patients with a history of CMVD have died. 
Causes of death were: intestinal allograft rejection with 
persistent CMVD at time of death in one patient. and 
posttransplant Iymphoproliferative disease (PTLD) in two 
patients with no evidence of CMVD at the time of death. 
The overall survival in patients (excluding D-/R-) with a 
history of CMVD as compared to patients without a history 
of CMVD was 70% vs 50%, respectively. The survival rates 
in the D-/R- cases was 60%. The overall graft survival 
(excluding D-/R-) in CMVD versus no CMVD was 70% 
and 44%, respectively. and 60% in D-/R- subgroup. 
CMVD occurred in three out of five patients without 
ganciclovir prophylaxis compared to seven out of 21 receiv-
ing ganeiclovir prophylaxis (P = NS by Fisher Exact Test). 
DISCUSSION 
We have observed important differences in CMV-associ-
ated morbidity and mortality in children as compared to 
adults undergoing ITx at our center. An equal frequency of 
disease occurred in our groups D+/R-, D+/R+. and 
D-/R+ pediatric ITx recipients. Also. CMVD was not 
associated with significant morbidity or increased mortality. 
This contrasts with adult ITx recipients where D+/R-
experienced severe morbidity and increased mortality from 
CMVD. There was, however, a trend towards more persis-
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tent CMVD involving the allograft of D + /R - children. 
Though these persistent episodes were not always symp-
tomatic, they took up to 7 months to resolve histologically. 
Mortality rates in patients with CMVD were not in-
creased. Deaths in patients with a history of CMVD were 
associated with rejection or PTLD. Successful clinical man-
agement of CMVD was accomplished in the 93% of 
episodes. Because of the concurrence of CMV and intesti-
nal allograft rejection, immunosuppression was maintained 
at a therapeutic baseline and reduced only in the face of 
clinical deterioration. Maintaining this baseline did not 
appear to exacerbate the CMVD. 
In summary, CMV negative donors are preferred for 
CMV seronegative ITx recipients because CMVD is a 
major contributing factor in morbidity in these children. 
The use of CMV negative donors eliminated CMVD in 
these CMV seronegative patients. However, when CMVD 
did occur, the use of appropriate antiviral and immunosup-
2771 
pressive management made it possible to mlDlmlZe its 
importance. CMV-associated mortality and graft loss did 
not occur in our patients, regardless of D/R CMV serologic 
status. Consequently, we recommend the use of CMV 
positive donors for our candidates with end-stage liver 
disease who require transplantation urgently and in whom a 
CMV -negative allograft can not be found. 
REFERENCES 
1. Abu Eigmad K, Todo S, Tzakis A, et al: J Am Coli Surg 
179(4):385, 1994 
2. Todo S, Tzakis AG, Abu Eigmad K, et al: Ann Surg 216:223, 
1992 
3. Todo S, Reyes J, Furukawa H, et al: Ann Surg 222(3):270, 
1995 
4. Manez R, Kusne S, Green M, et al: Transplantation 10lD, 
1995 
